Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • rare neurological disorders

    - PMLiVE

    BMS, Takeda and Astex join AI training consortium

    The initiative focuses on training AI models to aid in drug discovery and development

    EU flag

    EC approves argenx’s subcutaneous Vyvgart for rare autoimmune disease CIPD

    The drug has been authorised as a monotherapy for adults with progressive or relapsing active cases

    - PMLiVE

    Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

    The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

    - PMLiVE

    Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP

    The enzyme replacement therapy is now the first treatment approved in the UK for this patient population

    - PMLiVE

    MHRA approves Bavarian Nordic’s chikungunya vaccine Vimkunya

    Approximately 620,000 cases of the mosquito-borne viral disease were reported worldwide in 2024

    - PMLiVE

    Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma

    The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication

    - PMLiVE

    Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma

    Around 800 people in the UK are diagnosed with late-stage disease every year

    - PMLiVE

    Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer

    Up to 160,000 people in the US are affected by polycythaemia vera

    - PMLiVE

    Takeda and EU Innovative Health Initiative launch Crohn’s disease prevention study

    Approximately three million people in Europe are affected by inflammatory bowel disease

    - PMLiVE

    MHRA urges companies to prepare for Windsor Framework for medicines

    The new UK-wide arrangements for medicines will come into effect on 1 January 2025

    - PMLiVE

    Ipsen’s Iqirvo approved by MHRA to treat primary biliary cholangitis in adults

    Approximately 25,000 people in the UK are affected by the rare liver disease

    - PMLiVE

    Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine approved by MHRA

    The UK regulator has approved four versions of the updated vaccine for adults and children from infancy

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links